Literature DB >> 18577109

Prediction of clinically insignificant prostate cancer by detection of allelic imbalance at 6q, 8p and 13q.

Masataka Nakano1, Hiroyuki Takahashi, Taizo Shiraishi, Tomoe Lu, Masakuni Furusato, Shin Wakui, Hiroshi Hano.   

Abstract

The criterion tumor volume (TV) for clinically insignificant prostate cancer has been reported, but it differs from study to study: some have reported TV < 200 mm(3); others, < 500 mm(3). The aim of the present study was to distinguish clinically insignificant cancers from significant ones using molecular biological methods. A total of 184 microscopic cancers (MC) defined as limited within a 3 mm circle and 82 main tumor (MT) nodules were selected. Thirteen microsatellite loci at 6q22, 8p23.2-23, 13q14 and 13q33 were evaluated for loss of heterozygosity (LOH). MT were subgrouped as TV > or = 500 mm(3) or < 500 mm(3); TV > or = 200 mm(3) or < 200 mm(3); and TV < 200 mm(3), 200 mm(3) < or = TV < 500 mm(3) or TV > or = 500 mm(3); and frequencies of LOH were compared between these three groups. Frequencies of LOH at 6q16-21, 6q22, 8p23.1, 8p23.2, 13q14 were significantly lower in MC (1.0%, 2.7%, 1.9%, 1.1% and 5.4%) than in MT (30.9%, 40.4%, 12%, 8.7% and 20.6%), but no significant differences in LOH frequency were found within each of the three TV groups, between each cut-off. When insignificant tumor is defined as TV < 200 mm(3) or < 500 mm(3), it should include tumors with malignant potential equivalent to larger tumors. It is suggested that in order to identify insignificant tumor within a strict safety range, TV should be set lower.

Entities:  

Mesh:

Year:  2008        PMID: 18577109     DOI: 10.1111/j.1440-1827.2008.02246.x

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  2 in total

1.  Molecular cytogenetic characterization in four pediatric pheochromocytomas and paragangliomas.

Authors:  Ales Vicha; Milena Holzerova; Anna Krepelova; Zdenek Musil; Pavel Prochazka; David Sumerauer; Roman Kodet; Tomas Eckschlager; Marie Jarosova
Journal:  Pathol Oncol Res       Date:  2011-04-05       Impact factor: 3.201

2.  Contribution of ARLTS1 Cys148Arg (T442C) variant with prostate cancer risk and ARLTS1 function in prostate cancer cells.

Authors:  Sanna Siltanen; Tiina Wahlfors; Martin Schindler; Outi R Saramäki; John Patrick Mpindi; Leena Latonen; Robert L Vessella; Teuvo L J Tammela; Olli Kallioniemi; Tapio Visakorpi; Johanna Schleutker
Journal:  PLoS One       Date:  2011-10-20       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.